8-K
AbbVie Inc. (ABBV)
8-K
2023-01-10
For: 2023-01-10
View Original
Added on
April 02, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): January 10, 2023
ABBVIE INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35565 | 32-0375147 |
|---|---|---|
| (State or other Jurisdiction<br> of Incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:
(847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.01 Par Value | ABBV | New York Stock Exchange <br>Chicago Stock Exchange |
| 1.500% Senior Notes due 2023 | ABBV23B | New York Stock Exchange |
| 1.375% Senior Notes due 2024 | ABBV24 | New York Stock Exchange |
| 1.250% Senior Notes due 2024 | ABBV24B | New York Stock Exchange |
| 0.750% Senior Notes due 2027 | ABBV27 | New York Stock Exchange |
| 2.125% Senior Notes due 2028 | ABBV28 | New York Stock Exchange |
| 2.625% Senior Notes due 2028 | ABBV28B | New York Stock Exchange |
| 2.125% Senior Notes due 2029 | ABBV29 | New York Stock Exchange |
| 1.250% Senior Notes due 2031 | ABBV31 | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Common Stock, $0.01 Par Value | ABBV |
|---|
Item 7.01 Regulation FD Disclosure
On January 10, 2023, AbbVie Inc. posted an investor presentation to its website at: https://investors.abbvie.com/presentations. A copy is attached as Exhibit 99.1 to this Current Report on Form 8-K.
As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 incorporated herein shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Exhibit |
|---|---|
| 99.1 | Investor Presentation dated January 10, 2023. |
| 104 | The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABBVIE INC. | ||
|---|---|---|
| Date: January 10, 2023 | By: | /s/ Scott T. Reents |
| Scott T. Reents | ||
| Executive Vice President, Chief Financial Officer |
Exhibit 99.1
| J.P. Morgan Healthcare Conference | January 10, 2023<br>1<br>J.P. Morgan Healthcare Conference<br>Rick Gonzalez<br>Chairman and Chief Executive Officer<br>January 10, 2023 |
|---|---|
| J.P. Morgan Healthcare Conference | January 10, 2023<br>2<br>Forward<br>-<br>Looking Statements and Non<br>-<br>GAAP Financial Information<br>Some statements in this presentation are, or may be considered, forward<br>-<br>looking statements for purposes of the Private Securitie<br>s Litigation<br>Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or cond<br>iti<br>onal verbs,<br>generally identify forward<br>-<br>looking statements. AbbVie cautions that these forward<br>-<br>looking statements are subject to risks and un<br>certainties<br>that may cause actual results to differ materially from those expressed or implied in the forward<br>-<br>looking statements. Such risks<br>and<br>uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficul<br>tie<br>s inherent in the<br>research and development process, adverse litigation or government action, and changes to laws and regulations applicable to<br>our<br>industry.<br>Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’<br>s o<br>perations is<br>set forth in Item 1A, “Risk Factors,” of AbbVie's 2021 Annual Report on Form 10<br>-<br>K, which has been filed with the Securities and<br>Exchange<br>Commission, as updated by its Quarterly Reports on Form 10<br>-<br>Q and in other documents that AbbVie subsequently files with the Secu<br>rities<br>and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifica<br>lly<br>declines, to release publicly any revisions to forward<br>-<br>looking statements as a result of subsequent events or developments, exce<br>pt as<br>required by law.<br>This presentation contains GAAP and certain non<br>-<br>GAAP financial measures. Non<br>-<br>GAAP financial measures are adjusted for certain no<br>n<br>-<br>cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses and other specified items pre<br>sen<br>ted in<br>AbbVie’s reconciliation tables. AbbVie’s management believes non<br>-<br>GAAP financial measures provide useful information to investors<br>regarding AbbVie’s results of operations and assist management, analysts and investors in evaluating the performance of the b<br>usi<br>ness. Non<br>-<br>GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance p<br>rep<br>ared in<br>accordance with GAAP. Reconciliations of these non<br>-<br>GAAP financial measures to the most comparable GAAP measures are available in<br>the<br>appendix to this presentation and on the company’s website at www.abbvieinvestor.com.<br>Today’s discussions and presentation are intended for the investor community only; materials are not intended to promote the<br>pro<br>ducts<br>referenced herein or otherwise influence healthcare prescribing decisions. |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>3<br>Not for promotional use<br>AbbVie is a Diversified Biopharmaceutical Company with<br>Multiple Sources of Growth<br>Immunology<br>Oncology<br>Neuroscience<br>Aesthetics<br>Best<br>-<br>in<br>-<br>Class<br>medicines position<br>AbbVie for sustained<br>leadership;<br>Significant growth<br>potential for Skyrizi<br>and Rinvoq<br>Large, established<br>position in blood<br>cancer; Building a<br>broad pipeline across<br>a range of cancers for<br>long<br>-<br>term growth<br>Positioned for<br>significant growth with<br>attractive commercial<br>opportunities across<br>Migraine, Psychiatry<br>Neuro<br>-<br>Degeneration<br>Leadership positions<br>across core areas;<br>New products,<br>increasing penetration,<br>and global expansion<br>drive significant long<br>-<br>term growth<br>Eye Care<br>Large franchise<br>with investment<br>opportunities to<br>sustain leadership;<br>Drive growth through<br>internal and external<br>innovation<br>Clear Path to Long<br>-<br>Term Growth Following U.S. Humira LOE; Expect Return to Strong<br>Top<br>-<br>Line Growth in 2025, with High<br>-<br>Single Digit CAGR Through Remainder of Decade |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>4<br>Not for promotional use<br>A Unique Investment Opportunity With Strong Cash Flow to Support<br>Capital Allocation Priorities<br>Compelling capital<br>allocation philosophy,<br>balanced between<br>supporting growth<br>and returning capital<br>to shareholders<br>Continued R&D investment in promising, innovative<br>science across therapeutic categories, as well as<br>capacity to pursue additional pipeline assets to<br>augment the internal pipeline<br>Committed to a robust and growing dividend;<br>Increased quarterly dividend by 270% since<br>inception<br>Continued debt repayment to extinguish incremental<br>debt associated with Allergan transaction by end of<br>2023;<br>Expect to pay another $4B in maturities in<br>2023, bringing cumulative debt pay down to ~$34B |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>5<br>Not for promotional use<br>Immunology<br>Outstanding Execution of Strategy to Transform AbbVie Immunology From a Single<br>Product to a Portfolio Of Differentiated Therapies<br>RHEUM<br>DERM<br>GASTRO<br>RA<br>PsA<br>AS /<br>nr<br>-<br>axSpA<br>SLE<br>GCA<br>PsO<br>AD<br>HS<br>Vitiligo<br>Alopecia<br>CD<br>UC<br>Ph3<br>Ph3<br>Ready*<br>Ph3<br>Ph3<br>Ready*<br>Ph2<br>Ph3<br>Ready*<br>Currently Approved<br>Under Regulatory Review<br>*Expect to begin Ph3 studies in 2023<br>Early<br>-<br>Stage Immunology Programs<br>•<br>ABBV<br>-<br>154: Ph2 ongoing in PMR and CD<br>•<br>Lutikizumab Ph2 ongoing in HS; Plan to begin<br>Ph2 in UC in 2023<br>•<br>ABBV<br>-<br>668 Ph2 ongoing in CD<br>•<br>Acazicolcept<br>Ph2 ongoing in SLE<br>•<br>CUG<br>-<br>252 Ph1 ongoing with plans to develop in SLE<br>•<br>CLF065 Ph1 ongoing with plans to develop in IBD |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>6<br>Not for promotional use<br>Immunology<br>Skyrizi and Rinvoq Expected to Drive Significant Long<br>-<br>Term Growth<br>>$<br>17.5<br>B<br>>$<br>21<br>B<br>2025<br>2027<br>•<br>Adding new indications in 2020<br>-<br>2025 timeframe<br>and ramping to peak share 2025<br>-<br>2030<br>•<br>Now expect combined risk<br>-<br>adjusted 2025 global<br>sales of >$17.5 billion for Skyrizi and Rinvoq<br>o<br>Skyrizi >$10B<br>o<br>Rinvoq >$7.5B<br>•<br>Combined peak sales for Skyrizi and Rinvoq<br>expected to exceed Humira peak revenue<br>(>$21B) in 2027<br>$4.0B Rheum<br>$1.8B IBD<br>$1.7B AD<br>$7.5B PsO/PsA<br>$2.5B IBD<br>+ |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>7<br>Not for promotional use<br>Oncology<br>On<br>-<br>Market<br>Oncology Portfolio<br>Key Focus and<br>Priorities:<br>Maximize Imbruvica value in the face of increasing market and<br>competitive challenges<br>•<br>E<br>xpected to remain a key asset generating significant cash flow<br>Strengthen Venclexta’s position in CLL / AML and position for long<br>-<br>term growth<br>by broadening indications<br>•<br>Expect continued share gains in CLL and AML(unfit); Indication expansion in MM,<br>AML(fit), MDS represent meaningful growth drivers<br>Expect global oncology revenue to decline to ~$5.7B in 2023 and remain<br>relatively flat through 2024/2025, followed by a return to growth in 2026 as<br>new oncology products and indications ramp<br>Established Leader in Hematologic Oncology |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>8<br>Not for promotional use<br>Oncology<br>Oncology Pipeline<br>Key Focus and<br>Priorities:<br>Successfully develop and launch new assets to support return to growth<br>for Oncology portfolio<br>•<br>Epcoritamab<br>-<br>potential best<br>-<br>in<br>-<br>class CD3<br>-<br>CD20 bispecific across B cell<br>malignancies; anticipate initial approval in 3L+ DLBCL in 2023<br>*<br>•<br>Navitoclax<br>-<br>potential to improve symptoms, reverse fibrosis and modify the<br>course of myelofibrosis; anticipate approval in 2024<br>•<br>Teliso<br>-<br>V<br>-<br>potential to become an important new treatment option in non<br>-<br>small<br>cell lung cancer; anticipate approval in 2L+ NSCLC in 2024<br>*<br>Advance early<br>-<br>stage pipeline of novel heme and solid tumor assets to<br>support sustainable, long<br>-<br>term growth<br>•<br>Focused on<br>bi<br>-<br>specific, ADC platform<br>and<br>next<br>-<br>generation immuno<br>-<br>oncology<br>approaches<br>Strong Commitment to Advance Pipeline of Innovative Cancer Therapies<br>*Anticipate Accelerated Approval based on registration<br>-<br>enabling Ph2 trials |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>9<br>Not for promotional use<br>Oncology<br>Compelling Oncology Pipeline Expected to Drive Growth Over Long<br>-<br>Term<br>Heme<br>-<br>O<br>nc<br>Targets<br>Navitoclax<br>BCL<br>-<br>2 /<br>BCL<br>-<br>xL<br>Inhibitor<br>Epcoritamab<br>CD3<br>-<br>CD20<br>Bispecific<br>ABBV<br>-<br>383*<br>BCMA<br>-<br>CD3<br>Bispecific<br>ABBV<br>-<br>744<br>BET<br>Inhibitor<br>ABBV<br>-<br>453<br>BCL<br>-<br>2<br>Inhibitor<br>Proof of Concept in<br>2022<br>–<br>2023<br>Proof of Concept in<br>202<br>4<br>–<br>2025<br>Phase 3 /<br>Phase 3 Ready<br>Solid Tumor<br>Targets<br>ABBV<br>-<br>151**<br>GARP/<br>TGF<br>β<br>1<br>TTX<br>-<br>030<br>CD39<br>ABBV<br>-<br>514<br>CCR8<br>ABBV<br>-<br>CLS<br>-<br>579/484<br>PTPN2<br>ABBV<br>-<br>647**<br>PTK7<br>-<br>ADC<br>ABBV<br>-<br>400<br>cMET<br>ADC<br>Teliso<br>-<br>V<br>c<br>-<br>MET ADC<br>CLBR001/<br>SWI019<br>CD19<br>sCAR<br>-<br>T<br>ABBV<br>-<br>319<br>CD19/<br>Steroid ADC<br>ABBV<br>-<br>637<br>EGFR<br>BCL<br>-<br>xL<br>ADC<br>ABBV<br>-<br>706<br>SEZ6 ADC<br>*Achieved proof<br>-<br>of<br>-<br>concept in 2021. Dose ranging studies ongoing. Expect to begin Phase 3 studies in 2023<br>**Achieved proof<br>-<br>of<br>-<br>concept in 2022. Expect to begin Phase 2 studies in 2023.<br>Antibody Drug<br>Conjugates<br>Immuno<br>-<br>Oncology<br>Eftoza<br>TRAIL<br>Agonist |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>10<br>Not for promotional use<br>Neuroscience<br>Leading Portfolio with Options for Every Patient Across the Migraine Spectrum<br>Acute Migraine Treatment<br>•<br>Leading treatment for migraine<br>attacks providing rapid and<br>sustained pain relief, with<br>convenient dosing<br>•<br>Expect >$1B in peak sales<br>Migraine Prevention<br>•<br>Approved for episodic migraine;<br>chronic migraine under<br>regulatory review<br>•<br>Expect peak sales of >$1B<br>•<br>A unique foundational treatment<br>for prevention of chronic migraine<br>•<br>Development ongoing for<br>potential expansion into episodic<br>migraine |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>11<br>Not for promotional use<br>Neuroscience<br>Developing Innovative Therapies for Mood, Thought and Anxiety Disorders<br>•<br>Versatile atypical antipsychotic that provides strong<br>efficacy across multiple symptoms, with minimal impact on<br>weight, lipids and fasting blood glucose<br>•<br>Recently approved as an adjunctive treatment for major<br>depressive disorder, offering an optimal combination of<br>powerful efficacy and trusted tolerability<br>•<br>Now expect Vraylar peak revenue of approaching $5B<br>Pipeline Focused on Novel Dopamine Receptor Modulators for<br>Neuropsychiatric Conditions and SV2A Positive Modulators to Treat Cognitive<br>Impairment in a Range of Neuropsychiatric and Neurodegenerative Disorders<br>$<br>17<br>B<br>$<br>32<br>B<br>2022<br>2027<br>Global Psychiatry Market<br>*<br>*Based on Evaluate Pharma estimated sales |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>12<br>Not for promotional use<br>Neuroscience<br>Advancing an Innovative Pipeline for Neuro<br>-<br>Degenerative Diseases<br>•<br>ABBV<br>-<br>951<br>is a<br>potentially transformative improvement<br>to current treatment options for<br>patients with advanced Parkinson’s disease; Regulatory approvals anticipated in 2023;<br>Expect peak sales of >$1B<br>•<br>Discovery efforts focused on<br>preventing spread of Lewy bodies, removing existing<br>aggregates, and restoring cellular function<br>Parkinson’s<br>Disease<br>•<br>R&D focused on<br>optimized a<br>-<br>beta antibody approaches<br>in Alzheimer’s disease for<br>faster amyloid clearance with low ARIA and patient friendly dosing regimen, as well as<br>clearing intracellular tau aggregates<br>and<br>modulating neuroinflammatory response<br>•<br>Recently began Ph2 study in AD for lead a<br>-<br>beta antibody, ABBV<br>-<br>916<br>Alzheimer’s<br>Disease |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>13<br>Not for promotional use<br>Aesthetics<br>Market Leader in Global Aesthetics with Significant Growth Opportunities from New Product<br>Introduction, Increasing Market Penetration and Global Expansion<br>$14B Global Market with Low<br>Consumer Penetration and<br>Significant Growth Potential<br>Market Leading Positions in<br>Key Aesthetics Categories<br>Strategic Investments Drive Growth<br>•<br>Sustained investment in consumer acquisition and retention<br>•<br>Enhanced digital products & services through Allē loyalty program<br>•<br>Best<br>-<br>in<br>-<br>class injector training program to grow base of skilled providers<br>•<br>International expansion to develop high growth markets including<br>China, Japan and Latin America<br>Continued Innovation through R&D Programs<br>and Business Development<br>•<br>Innovative Toxin Pipeline: Short<br>-<br>and long<br>-<br>acting toxins<br>•<br>Dermal Filler Expansion: Bio<br>-<br>stimulatory and regenerative fillers<br>•<br>Body Contouring: Soliton for cellulite and CoolSculpting enhancements<br>Expect Global Aesthetics sales of >$9B in 2029<br>Source: Medical Insight, Inc. Global Aesthetic Market Study November 2021 and AbbVie data. |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>14<br>Not for promotional use<br>Eye Care<br>Eye Care Portfolio<br>Key Focus and<br>Priorities:<br>Strong Foundation with Broad Portfolio Across Retina, Glaucoma, Refractive, Dry Eye and<br>Consumer Eye Care Generates Significant Cash Flow for Investment<br>•<br>Enhance standard<br>-<br>of<br>-<br>care in chronic retinal conditions with RGX<br>-<br>314, a<br>potential one<br>-<br>time gene therapy<br>•<br>Establish new treatments in geographic atrophy and explore vision restoration<br>RETINA<br>•<br>Optimize drop<br>-<br>free interventions (<br>Durysta<br>, Xen,<br>Prostamide<br>408 SR)<br>•<br>Explore neuroprotective MOAs to preserve and regenerate the optic nerve<br>GLAUCOMA<br>•<br>Improve standard of care through pursuit of differentiated MOAs<br>(AGN<br>-<br>242428<br>ROR<br>g<br>) and novel sustained release platforms<br>DRY EYE<br>CONSUMER<br>REFRACTIVE<br>•<br>Explore novel topical drops to provide enhanced benefits for presbyopia<br>•<br>Pursue next<br>-<br>generation corneal regenerative therapies<br>•<br>Innovate Artificial Tears with novel ingredients and new presentations<br>•<br>Expand into adjacent areas (e.g., allergy, ocular health) |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>15<br>Not for promotional use<br>Innovation<br>-<br>Driven R&D Organization<br>Proven Track Record of Developing New Medicines That<br>Consistently Elevate the Standard of Care<br>240+<br>Clinical<br>Trials<br>5<br>Core Therapeutic<br>Areas<br>13K+<br>R&D<br>Employees<br>80+<br>Clinical<br>Programs<br>~50<br>New Molecular<br>Entities<br>75+<br>Conditions<br>Treated<br>25<br>Major Product or Indication<br>Approvals*<br>110+<br>New Study Starts<br>Planned for 2023<br>*Reflects approvals since 2013 |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>16<br>Not for promotional use<br>AbbVie Pipeline<br>As of January 10, 2023<br>Excludes devices in development<br>*Partnered assets; See appendix for partnership summary<br>■<br>CUG<br>-<br>252* (IL<br>-<br>2 Mutein) SLE<br>■<br>CLF065* (GLP<br>-<br>2 agonist) IBD<br>■<br>ABBV<br>-<br>151 (GARP+TGF<br>b<br>1) Solid Tumors<br>■<br>ABBV<br>-<br>400 (cMet ADC) NSCLC<br>■<br>ABBV<br>-<br>647* (PTK7 ADC) NSCLC<br>■<br>ABBV<br>-<br>637 (EGFR BCL<br>-<br>xL<br>ADC) NSCLC<br>■<br>ABBV<br>-<br>706 (SEZ6 ADC) SCLC<br>■<br>ABBV<br>-<br>181 (PD<br>-<br>1) Solid Tumors<br>■<br>ABBV<br>-<br>927 (CD40) Solid Tumors<br>■<br>JAB<br>-<br>3312* (SHP2) Solid Tumors<br>■<br>TTX<br>-<br>030* (CD39) Solid Tumors<br>■<br>ABBV<br>-<br>CLS<br>-<br>579* (PTPN2) Solid Tumors<br>■<br>ABBV<br>-<br>CLS<br>-<br>484* (PTPN2) Solid Tumors<br>■<br>ABBV<br>-<br>514 (CCR8) Solid Tumors<br>■<br>Eftoza (TRAIL) Heme Tumors<br>■<br>ABBV<br>-<br>319 (CD19/Steroid ADC) Heme Tumors<br>■<br>ABBV<br>-<br>525 (MALT1) Heme Tumors<br>■<br>CLBR001/SWI019* (<br>sCAR<br>-<br>T) Heme Tumors<br>■<br>ABBV<br>-<br>383 (CD3<br>-<br>BCMA) MM<br>■<br>HPN<br>-<br>217* (CD3<br>-<br>BCMA) MM<br>■<br>ABBV<br>-<br>453 (BCL<br>-<br>2) R/R MM t(11;14)<br>■<br>ABBV<br>-<br>744 (BET) MF<br>■<br>ABBV<br>-<br>552 (SV2A) Alzheimer’s Disease<br>■<br>ABBV<br>-<br>CLS<br>-<br>7262* (elF2B) Multiple Neuro<br>■<br>AGN<br>-<br>241622 (Alpha2) Presbyopia<br>■<br>ABBV<br>-<br>1882 (anti<br>-<br>PD1/anti<br>-<br>a4b7) HIV<br>■<br>ABBV<br>-<br>903 (<br>MPro<br>Inhibitor) COVID<br>■<br>ABBV<br>-<br>154 (TNF<br>-<br>Steroid ADC) PMR<br>■<br>ABBV<br>-<br>154 (TNF<br>-<br>Steroid ADC) CD<br>■<br>Rinvoq (JAK 1) Vitiligo<br>■<br>Rinvoq (JAK 1) SLE<br>■<br>Rinvoq (JAK 1) HS<br>■<br>Acazicolcept ALPN<br>-<br>101* (ICOS/CD28) SLE<br>■<br>Lutikizumab (IL<br>-<br>1<br>a<br>/1<br>b<br>) HS<br>■<br>ABBV<br>-<br>668 (RIPK1) UC<br>■<br>ABBV<br>-<br>CX<br>-<br>2029* (CD71) Solid/Heme Tumors<br>■<br>ABBV<br>-<br>916 (a<br>-<br>beta) Alzheimer’s Disease<br>■<br>Botox (SNARE) Essential Tremor<br>■<br>Elezanumab (<br>RGMa<br>) Stroke<br>■<br>Elezanumab (<br>RGMa<br>) SCI<br>■<br>AL002* (TREM2) AD<br>■<br>OnabotA X (SNARE) Glabellar Lines<br>■<br>OnabotA X (SNARE) Forehead Lines<br>■<br>AGN<br>-<br>242428 (<br>ROR<br>g<br>) Dry Eye<br>■<br>ABBV<br>-<br>RGX<br>-<br>314* (NAV AAV8 Anti<br>-<br>VEGF Fab)<br>wAMD<br>Suprachoroidal Delivery<br>■<br>ABBV<br>-<br>RGX<br>-<br>314* (NAV AAV8 Anti<br>-<br>VEGF Fab) DR<br>Suprachoroidal Delivery<br>■<br>AGN<br>-<br>193408 (<br>Prostamide<br>408 SR) Glaucoma<br>■<br>CF Triple Combo (CFTR<br>-<br>C1/CFTR<br>-<br>C2/CFTR<br>-<br>P)<br>■<br>Armour<br>Thyroid (T3T4) Hypothyroidism<br>■<br>AGN<br>-<br>151607 (SNARE) Atrial Fibrillation<br>■<br>Botox (SNARE) IC/BPS<br>■<br>Rinvoq (JAK 1) GCA<br>■<br>Skyrizi* (IL<br>-<br>23) UC<br>■<br>Imbruvica* (BTK) 1L FL<br>■<br>Imbruvica* (BTK) R/R MCL<br>■<br>Imbruvica* (BTK) + Venclexta* (BCL<br>-<br>2) R/R MCL<br>■<br>Venclexta* (BCL<br>-<br>2) AML Maintenance<br>■<br>Venclexta* (BCL<br>-<br>2) R/R MM t(11;14)<br>■<br>Venclexta* (BCL<br>-<br>2) High Risk MDS<br>■<br>Navitoclax (BCL<br>-<br>2/BCL<br>-<br>xL<br>) Myelofibrosis<br>■<br>Epcoritamab* (CD3<br>-<br>CD20) 1L DLCBL<br>■<br>Epcoritamab* (CD3<br>-<br>CD20) R/R DLBCL<br>■<br>Epcoritamab* (CD3<br>-<br>CD20) R/R FL<br>■<br>Teliso<br>-<br>V* (cMet ADC) NSCLC<br>■<br>Botox (SNARE) Episodic Migraine<br>■<br>BoNT/E (SNARE) Glabellar Lines<br>■<br>Botox (SNARE) Masseter Prominence<br>■<br>Botox (SNARE) Platysma Prominence<br>■<br>ABBV<br>-<br>RGX<br>-<br>314* (NAV AAV8 Anti<br>-<br>VEGF Fab)<br>wAMD<br>Subretinal Delivery<br>■<br>Aztreonam/Avibactam* (PBP3) Infection<br>■<br>Rinvoq (JAK 1) CD<br>■<br>Epcoritamab* (CD3<br>-<br>CD20): R/R DLBCL<br>■<br>ABBV<br>-<br>951 (dopamine receptor) PD<br>■<br>Qulipta (CGRP) Chronic Migraine Prevention<br>Phase 1<br>Phase 2<br>Registrational / Phase 3<br>Submitted<br>■<br>Immunology<br>■<br>Oncology<br>■<br>Neuroscience<br>■<br>Aesthetics<br>■<br>Eye Care<br>■<br>Targeted Investment |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>17<br>Not for promotional use<br>Anticipated Key Pipeline Events<br>2023<br>2024<br>Regulatory<br>Approvals<br>Rinvoq CD<br>Epcoritamab 3L R/R DLBCL (AA)<br>ABBV<br>-<br>951 Advanced PD<br>Qulipta Chronic Migraine Prevention<br>Skyrizi UC<br>Venclexta 3L+ MM w/ t(11;14)<br>Venclexta High Risk MDS<br>Navitoclax 1L MF<br>Teliso V 2L+ NSCLC (AA)<br>Botox Platysma<br>Botox Masseter<br>Regulatory<br>Submissions<br>Skyrizi UC<br>Venclexta 3L+ MM w/ t(11;14)<br>Navitoclax 1L MF<br>Botox Platysma<br>Botox Masseter<br>Rinvoq GCA<br>Teliso<br>-<br>V NSCLC<br>Venclexta High Risk MDS<br>Navitoclax r/r MF<br>Botox Episodic Migraine<br>BoNT/E (Short<br>-<br>Acting Toxin) Glabellar Lines<br>Ph3/Registrational<br>Data Readouts<br>Skyrizi UC Induction/Maintenance<br>Venclexta Ph3 3L+ MM t(11;14) (CANOVA)<br>Navitoclax Ph3 1L MF (Transform<br>-<br>1)<br>Epcoritamab Ph3 3L DLBCL<br>Teliso<br>-<br>V Ph2 2L+ NSCLC<br>Botox Ph3 Masseter<br>Botox Ph3 Platysma<br>BoNT/E (Short<br>-<br>Acting Toxin) Ph3 Glabellar Lines<br>Rinvoq Ph3 GCA<br>Venclexta Ph3 High Risk MDS<br>Navitoclax Ph3 r/r MF (Transform<br>-<br>2)<br>Botox Ph3 Episodic Migraine<br>ABBV<br>-<br>RGX<br>-<br>314 Ph3<br>wAMD<br>SR<br>Early / Mid Stage<br>Data Readouts<br>Rinvoq Vitiligo<br>ABBV<br>-<br>154 (TNF<br>-<br>Steroid ADC) Ph2 PMR<br>TTX<br>-<br>030 (CD39) Ph1 Solid Tumors<br>CLBR001/SWI019 (CD19<br>sCAR<br>-<br>T) Ph1 Heme Tumors<br>Eftoza (Trail) Ph1 Heme Tumors<br>ABBV<br>-<br>637 (EGFR BCL<br>-<br>xLi<br>ADC) Ph1 NSCLC<br>AGN<br>-<br>241622 (Alpha2) Presbyopia<br>ABBV<br>-<br>154 (TNF<br>-<br>Steroid ADC) Ph2 CD Induction<br>Lutikizumab<br>(IL<br>-<br>1<br>a<br>/1<br>b<br>)<br>Ph2 HS<br>ABBV<br>-<br>CLS<br>-<br>579 (PTPN2) Ph1 Solid Tumors<br>ABBV<br>-<br>CLS<br>-<br>484 (PTPN2) Ph1 Solid Tumors<br>ABBV<br>-<br>400<br>(c<br>-<br>Met ADC)<br>Ph1 Solid Tumors<br>ABBV<br>-<br>453 (BCL<br>-<br>2) Ph1 MM t(11;14)<br>ABBV<br>-<br>744 (BET) Ph1 MF<br>Elezanumab (<br>RGMa<br>) Ph2 Stroke<br>ABBV<br>-<br>552 (SV2A) Ph2 AD Cognition<br>ABBV<br>-<br>CLS<br>-<br>7262 (elF2B) Ph2 ALS<br>As of January 10, 2023<br>AA = Accelerated Approval |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>18<br>Not for promotional use<br>Portfolio of leading brands in attractive and sustainable markets<br>Pipeline of innovative, highly differentiated assets to address significant<br>unmet needs, with potential to drive significant growth<br>Compelling capital allocation philosophy balanced between supporting<br>growth and returning capital to shareholders<br>Track record of strong execution, consistently meeting or exceeding financial<br>commitments to deliver industry leading financial performance<br>A unique investment vehicle, offering top<br>-<br>tier revenue and EPS growth,<br>significant cash flow and strong return of capital to shareholders<br>AbbVie: A Unique Investment Opportunity Poised for Continued<br>Strong Shareholder Returns |
| --- | |
| J.P. Morgan Healthcare Conference | January 10, 2023<br>20<br>AbbVie’s Partnered Assets<br>•<br>ABBV<br>-<br>2029<br>developed<br>by<br>CytomX<br>Therapeutics<br>through<br>clinical<br>proof<br>of<br>concept<br>and<br>AbbVie<br>holds<br>option<br>for<br>additional<br>development<br>•<br>ABBV<br>-<br>647<br>developed<br>in<br>cooperation<br>with<br>Pfizer<br>•<br>ABBV<br>-<br>CLS<br>-<br>579<br>/<br>484<br>/<br>7262<br>co<br>-<br>developed<br>by<br>Calico<br>and<br>AbbVie<br>•<br>Acazicolcept<br>(ALPN<br>-<br>101<br>)<br>developed<br>by<br>Alpine<br>Immune<br>Sciences<br>through<br>current<br>Phase<br>2<br>study<br>and<br>AbbVie<br>holds<br>option<br>for<br>additional<br>development<br>•<br>AL<br>002<br>developed<br>by<br>Alector<br>through<br>Phase<br>2<br>and<br>AbbVie<br>holds<br>option<br>for<br>additional<br>development<br>•<br>Aztreonam/Avibactam<br>co<br>-<br>developed<br>by<br>Pfizer<br>and<br>AbbVie<br>•<br>CLBR<br>001<br>/SWI<br>019<br>developed<br>by<br>Calibr<br>in<br>a<br>first<br>-<br>in<br>-<br>patient<br>trial<br>and<br>AbbVie<br>holds<br>option<br>for<br>additional<br>development<br>•<br>CLF<br>065<br>developed<br>by<br>Scripps/Calibr<br>in<br>a<br>first<br>-<br>in<br>-<br>patient<br>trial<br>and<br>AbbVie<br>holds<br>option<br>for<br>additional<br>development<br>•<br>CUG<br>-<br>252<br>developed<br>by<br>Cugene<br>through<br>Phase<br>1<br>b<br>and<br>AbbVie<br>holds<br>option<br>for<br>additional<br>development<br>•<br>Epcoritamab<br>developed<br>in<br>partnership<br>with<br>Genmab<br>•<br>HPN<br>-<br>217<br>developed<br>by<br>Harpoon<br>through<br>Phase<br>1<br>/<br>2<br>and<br>AbbVie<br>holds<br>option<br>for<br>additional<br>development<br>•<br>Imbruvica<br>jointly<br>developed<br>with<br>Janssen<br>Biotech<br>•<br>JAB<br>-<br>3312<br>developed<br>in<br>partnership<br>with<br>Jacobio<br>•<br>RGX<br>-<br>314<br>co<br>-<br>developed<br>by<br>REGENXBIO<br>and<br>AbbVie<br>•<br>Skyrizi<br>developed<br>in<br>cooperation<br>with<br>Boehringer<br>Ingelheim<br>•<br>Teliso<br>-<br>V<br>licensed<br>from<br>Seagen<br>and<br>Pierre<br>Fabre<br>•<br>TTX<br>-<br>030<br>developed<br>by<br>Trishula<br>Therapeutics<br>through<br>Phase<br>1<br>b<br>and<br>AbbVie<br>has<br>option<br>to<br>lead<br>global<br>development<br>•<br>Venclexta<br>jointly<br>developed<br>with<br>Roche<br>•<br>Vraylar<br>developed<br>in<br>cooperation<br>with<br>Gedeon<br>Richter |
| --- |